Get the Stockscreener App
2.71
16.31%
0.38
After Hours:
2.63
-0.08
-2.95%
Indaptus Therapeutics Inc stock is traded at $2.71, with a volume of 46,439.
It is up +16.31% in the last 24 hours and up +53.11% over the past month.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.
See More
Previous Close:
$2.33
Open:
$2.27
24h Volume:
46,439
Relative Volume:
0.93
Market Cap:
$6.08M
Revenue:
-
Net Income/Loss:
$-20.85M
P/E Ratio:
-0.1679
EPS:
-16.1435
Net Cash Flow:
$-15.72M
1W Performance:
+72.61%
1M Performance:
+53.11%
6M Performance:
-30.15%
1Y Performance:
+437.38%
1-Day Range:
$2.2201
$2.73
1-Week Range:
$1.51
$2.73
52-Week Range:
$0.2701
$13.40
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Name
Indaptus Therapeutics Inc
Sector
Industry
Phone
(646) 427-2727
Address
3 COLUMBUS CIRCLE, NEW YORK
Compare INDP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
2.71 | 5.22M | 0 | -20.85M | -15.72M | -16.14 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Indaptus Therapeutics Inc Stock (INDP) Latest News
Momentum Shift: Should I hold or sell Indaptus Therapeutics Inc nowInflation Watch & Daily Stock Trend Watchlist - baoquankhu1.vn
Published on: 2026-04-13 10:12:55 - baoquankhu1.vn
[SCHEDULE 13G/A] Indaptus Therapeutics, Inc. Amended Passive Investment Disclosure - Stock Titan
Risk Off: Why is Indaptus Therapeutics Inc stock going up2026 Volume Leaders & High Yield Equity Trading Tips - baoquankhu1.vn
Indaptus Therapeutics, Inc. (INDP) stock news today: Live updates - Bitget
Indaptus Therapeutics Appoints Yu Ding as New Chief Financial Officer Effective April 2026 - Minichart
Indaptus Therapeutics Names New CFO, Refreshes Board Oversight - The Globe and Mail
Indaptus Therapeutics announces CFO transition and new board appointment - Investing.com
INDP Technical Analysis & Stock Price Forecast - Intellectia AI
Indaptus Therapeutics announces CFO transition and new board appointment By Investing.com - Investing.com South Africa
Indaptus appoints Yu Ding as CFO; Nir Sassi resigns - TradingView — Track All Markets
Indaptus Therapeutics (INDP) names new CFO and independent director - Stock Titan
Indaptus Therapeutics Inc. (INDP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Yun Yao converts preferred into 41.99M Indaptus (INDP) shares - Stock Titan
SINO LION VENTURES (INDP) discloses 38.9M-share Indaptus stake via preferred conversion - Stock Titan
Indaptus (INDP) CEO converts preferred stock into 11.25M common shares - Stock Titan
Volatility Watch: Is Indaptus Therapeutics Inc stock undervalued right now2026 Catalysts & Advanced Swing Trade Entry Plans - baoquankhu1.vn
Risk Hedge: Whats next for Indaptus Therapeutics Inc stock2026 Action & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Revenue Check: Why is Indaptus Therapeutics Inc stock going upTrade Risk Assessment & Stepwise Entry/Exit Trade Alerts - baoquankhu1.vn
New investor group takes large control stake in Indaptus Therapeutics (INDP) - Stock Titan
Yun Yao Leads Investor Group, Secures CEO Change at Indaptus Therapeutics, Inc. with 37.8% Stake - TradingView
Market Pulse: Why is Indaptus Therapeutics Inc stock going downWeekly Risk Summary & Safe Entry Zone Tips - baoquankhu1.vn
Rate Cut: Should I hold or sell Indaptus Therapeutics Inc nowTrade Analysis Report & AI Powered Market Entry Ideas - baoquankhu1.vn
Indaptus Therapeutics : 10-K 2025 Annual Report - marketscreener.com
Insider Buyers Lose US$40k As Indaptus Therapeutics Sheds US$583k - simplywall.st
Indaptus Therapeutics, Inc. Files Form 8-K Reporting Changes in Control – Key SEC Filing Details 3 - Minichart
Indaptus Therapeutics (INDP) shifts control and names Junyi Dai CEO-Chair - Stock Titan
Indaptus Therapeutics, Inc. Announces CEO Changes - MarketScreener
Lazar cuts Indaptus (NASDAQ: INDP) preferred stake, resigns as co‑CEO but stays on board - Stock Titan
Indaptus (INDP) director exits Series AAA stake, trims Series AA - Stock Titan
Short Covering: Does Indaptus Therapeutics Inc have declining or rising EPS2026 Major Catalysts & Safe Entry Zone Identification - baoquankhu1.vn
Market Outlook: Does Indaptus Therapeutics Inc have declining or rising EPSPortfolio Performance Report & Trade Opportunity Analysis Reports - baoquankhu1.vn
Indaptus Therapeutics, Inc. 2025 Annual Report: Company Overview, Risks, Investment Transaction, and Regulatory Compliance - Minichart
Indaptus Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Lazar-backed Indaptus Therapeutics (NASDAQ: INDP) halts trials, eyes strategic deal - Stock Titan
CEO Change: Will PANL stock hit new highs in YEAR2026 Sector Moves & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-03-17 18:45:40 - baoquankhu1.vn
Indaptus Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
INDPIndaptus Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Indaptus Therapeutics (INDP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Why Indaptus Therapeutics Inc. stock remains on buy listsWeekly Stock Report & Safe Entry Momentum Tips - Naître et grandir
Will Indaptus Therapeutics Inc. stock keep outperforming rivalsWeekly Trade Summary & Safe Entry Zone Identification - Naître et grandir
Indaptus Therapeutics Inc expected to post a loss of $4.36 a shareEarnings Preview - TradingView
Does Indaptus Therapeutics Inc. have declining or rising EPSPortfolio Profit Report & Daily Stock Momentum Reports - Mfd.ru
Why Did INDP Stock Gain 12% Today? - Stocktwits
Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday - Defense World
CapEx per share of Indaptus Therapeutics, Inc. – NASDAQ:INDP - TradingView
Lazar takes 98% control stake in Indaptus Therapeutics (INDP) via $6M deal - Stock Titan
Indaptus Therapeutics, Inc. Announces $3.0 Million Registered Direct Offering and Concurrent Private Placement - marketscreener.com
Indaptus Shareholders Approve Major Charter and Capital Changes - The Globe and Mail
Indaptus Therapeutics shareholders approve preferred stock conversion and company charter amendments - Investing.com
Indaptus Therapeutics Inc Stock (INDP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):